About MicuRx
Our company
Our Team
Vision & mission
History
Contact Us
Scientific research
Antibiotic Resistance
Kidney Disease
MicuRx R&D
Publications
Pipeline
Newsroom
Corporate news
Careers
Contact Us
中
Pharmacokinetics and Disposition of Contezolid in Humans: Resolution of a Disproportionate Human Metabolite for Clinical Development
Time:2021-10-18 / View:281 times
Prev:
Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity
Next:
A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In Vitro
Back
Close